Navigation Links
Dr. Anthony Fauci reflects on 25 years of HIV
Date:5/15/2008

On the 25th anniversary of the first scientific article linking a retrovirus to AIDS, Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, reflects in an essay in Nature on his experience treating and studying HIV/AIDS for the past quarter century. Outlining the peaks and valleys of the scientific communitys journey so far, Dr. Fauci writes, we must learn from our mis-steps, build on our successes in treatment and prevention, and renew our commitment to developing the truly transforming tools that will one day put this scourge behind us.

From the outset, AIDS was clearly more menacing than any other novel disease Dr. Fauci and his colleagues had previously encountered, he writes. The period when clinicians lacked the ability to diagnose and treat AIDS was the bleakest of his career. The discovery that HIV causes AIDS stimulated a burst of progress in both the clinic and the laboratory. But the 1987 debut of the first effective drug against HIV, zidovudine (AZT), generated excessive optimism, Dr. Fauci reflects, as the virus quickly and predictably developed drug resistance.

Eight years and thousands of AIDS deaths later, protease inhibitors launched a renaissance of anti-HIV drug development in 1995. Combination therapies dramatically cut the rate of AIDS deaths in the United Statesbut the developing world has continued to suffer from lack of access to effective treatments for HIV. Even more sobering, Dr. Fauci writes, Treatment alone will never end the AIDS pandemicaround three people are newly infected for every person put on therapy.

So what options remain? Dr. Fauci praises research aimed at finding a cure for HIV/AIDS and affirms that this work must continue, but he places considerable hope and energy in preventing HIV infection, most importantly through the development of a vaccine. In retrospect, he writes, the scientific community expected
'/>"/>

Contact: NIAID Office of Communications
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Siemens Building Technologies Pioneers Wireless Solution for St. Anthonys Sensitive Environment
2. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
3. The Greening of St. Anthonys
4. iCAD, Inc. Appoints Anthony F. Ecock to Board of Directors
5. Teen Suicides Up Sharply for First Time in Years
6. A chocolate cookie a day puts 20 pounds on an energetically-balanced kid in 4 years
7. 6 Years Later, 9/11 Health Questions Linger
8. Health Insurance Premiums Rise 6.1 Percent in 2007, Less Rapidly Than in Recent Years But Still Faster Than Wages and Inflation
9. LOreal Paris Celebrates Ten Years of Hope and Healing
10. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
11. Texas Aviation Services: Over 20 Years of Creating Flying Emergency Rooms for Airborne EMS Customers in US and Latin America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Millennium Treatment Group is ... This month will be a celebration of the ... services. Along with other treatment facilities and mental ... spread the word about this national observance. , ... work of treatment and recovery professionals, and has ...
(Date:8/28/2014)... FL (PRWEB) August 28, 2014 Millennium ... use affecting users in the workplace. A recent ... Dependence (NCADD) states that drug abuse is costing ... who use or are addicted to drugs affect their ... activities carry over into the workplace, causing expensive problems ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. 28, 2014 ... worsen symptoms of multiple sclerosis (MS), a new study from ... vitamin D, smoking and Epstein Barr virus infection. Our study ... affecting MS patients," said lead researcher Dr. Mauricio Farez, of ... Multiple sclerosis is a disease of the nervous system ...
(Date:8/28/2014)... York, New York (PRWEB) August 28, 2014 ... second federal bellwether trial of a transvaginal mesh ... by Ethicon, Inc., Bernstein Liebhard LLP reports. Court ... District of West Virginia indicate that the case ... had to undergo two revision surgeries, allegedly due ...
(Date:8/28/2014)... August 28, 2014 Allegheny ... today a regional partnership designed to advance sports ... for competitive young athletes, scholastic athletes and their ... Strong Body & Mind Initiative will offer a ... the physical and mental dynamics involved in pursuing ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Drug Use Causes Problems in the Workplace 2Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4
... N.C., Nov. 2 Just how much of the time,that ... due to,administrative tasks and internal communication? Pharmaceutical sales directors ... of the time used for internal communication - or 6 ... in lost sales every year,according to a recent research study ...
... HILL, N.C., Nov. 2 Records and Information,Management ... in the success of,their parent organizations through reducing ... Today the programs account for,over $1.5 million in ... leader,Best Practices, LLC. This number will continue ...
... each point scored, CENTENNIAL, Colo., Nov. 2 ... show support for their favorite team -- camping,out for ... for the big game. Now five football teams are ... of a deadly disease --,prostate cancer. The Denver ...
... Inc.,(Nasdaq: IDMI ) today announced the presentation of ... patients,with lung metastases as a result of the progression ... typically affects children and young,adults. The data show that ... exhibited signs of disease control. "These results are ...
... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced ... for review the Company,s New Drug,Application (NDA) for NEBIDO(R), ... hypogonadism. The FDA Prescription,Drug User Fee Act (PDUFA) target ... was submitted to the FDA by the Company on ...
... Corporation,(Nasdaq: MNKD ), focused on discovering, developing and commercializing,treatments ... at,the following conferences: * The Acumen BioFin Rodman & ... November 6, 2007 at 2:20 PM ET at the New ... * The CIBC 18th Annual Healthcare Conference on Wednesday ...
Cached Medicine News:Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:New Records & Information Management: Are You Spending Right on Records Management, Data Security and Compliance? 2Health News:Professional Football Takes the Field to Tackle Prostate Cancer 2Health News:Professional Football Takes the Field to Tackle Prostate Cancer 3Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 2Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 3Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 4Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 5Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 6Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 7Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 2Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 3Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 4
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- Gateway Analytical announced ... 9 th Annual Global Pharma Manufacturing Summit ... 8-9 th . The Global Pharma Manufacturing Summit ... small molecule and biologic pharmaceutical manufacturing. The conference ... today,s manufacturers face, such as the increasing pressure ...
(Date:8/28/2014)... , Aug. 28, 2014  Robotic surgery is ... media, both for the promise of improved outcomes ... quick deployment of surgical robots and market pressures ... facilities to evaluate their robotic surgery training programs ... team.    ECRI Institute ( www.ecri.org ...
(Date:8/28/2014)... THOUSAND OAKS, Calif. , Aug. 28, 2014 /PRNewswire/ ... the submission of a Biologics License Application (BLA) to ... seeking approval for the treatment of high cholesterol. Evolocumab ... proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that ... (LDL-C), or "bad" cholesterol, from the blood. 1 ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... Mass. , July 26 The Exergen ... nationwide that stock the Exergen TemporalScanner™, according to data ... of all types of thermometers, including national brands and ... found Exergen came out on top. Exergen,s retail unit ...
... , NEWARK, Del. and GRONINGEN, Netherlands ... a leading full-service GLP/GCP-compliant contract research organization providing testing ... announced the completion of its acquisition of Xendo Drug ... .  XDD, a European contract research organization (CRO), will ...
Cached Medicine Technology:Exergen TemporalScanner Thermometer Best Selling Brand at Retailers 2QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4
... Introducing the new PRONEB® ULTRA compressor. ... treatment time while delivering more medication to ... PARI LC PLUS® or PARI LC STAR® ... are optimized for inhalation and retention into ...
... Compressed Air., ,Allied Healthcares Timeter® PCS 414 ... other air compressors that you may wonder if ... PCS 414 features a durable, mar-resistant steel case ... unit weighs only 26.5 pounds. The PCS 414 ...
... DC powered compressor nebulizer system available. ... to take nebulizer treatments away from ... the included AC power adapter or ... The integral reusable jet nebulizer kit ...
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
Medicine Products: